跳至主要内容
临床试验/CTRI/2010/091/000276
CTRI/2010/091/000276已完成未知

A randomized, double blind, double dummy four period crossover study to determine the therapeutic equivalence of a test HFA formulation of Salbutamol Sulphate (Azmasol HFA, Beximco Pharma) with the reference HFA formulation of Salbutamol Sulphate (Ventolin Evohaler, supplied by Allen & Hanburys, UK) in subjects with stable mild to moderate asthma.

Callisto Consulting0 个研究点目标入组 124 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
124

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Aged 20 to 70 years
  • 2. Stable Mild to Moderate Asthmatics for at least 12 months
  • 3. Regular use of short-acting inhaled beta-adrenoceptor agonists
  • 4. FEV1 values 60 to 80% of predicted values
  • 5. Capable of giving Informed Consent

排除标准

  • 1. Change in treatment of asthma within 4 weeks of start of study
  • 2. Treatment with drug which might effect the results of the trial
  • 3. Upper Respiratory Tract Infections
  • 4. Fixed airways disease
  • 5. Inability to use an inhaler correctly or to withhold bronchodilators for 8 hours
  • 6. No treatment at Accident & Emergency Unit or Hospital Admission within 1 week of start of study
  • 7. Myocardial infarction in the last 3 months
  • 8. Uncontrolled Hypertension
  • 9. History of Epilepsy
  • 10. History of Tuberculosis
  • 11. Current smokers or those who have smoked within the last 6 months or those who have a significant smoking history
  • 12. Pregnant or lactating women
  • 13. Involvement in other clinical trial in last three months
  • Subjects in whom blood drawing is not possible or justifiable in the opinion of Investigator

研究者

发起方
Callisto Consulting

相似试验